Literature DB >> 32182489

Discovery of aryl-piperidine derivatives as potential antipsychotic agents using molecular hybridization strategy.

Chen Zhu1, Xinwei Li1, Bangyi Zhao1, Weiqing Peng1, Wei Li1, Wei Fu2.   

Abstract

Schizophrenia is a chronic, disabling mental disorder that affects about one percent of world's population. Drugs acting on multiple targets have been demonstrated to provide superior efficacy in schizophrenia than agents acting on single target. In this study, based on FW01, a selective potent 5-HT1A receptor agonist discovered via dynamic pharmacophore-based virtual screening, molecular hybridization strategy was employed to optimize its in vitro activity over D2 and 5-HT2A receptors. The optimized compound 9f was found to show dual potent D2 and 5-HT2A receptors antagonistic activity. In addition, compound 9f showed good in vivo metabolic stability with t1/2 of 2 h in ICR mice and good capability to penetrate the blood-brain barrier with Kp value of 4.03. These results demonstrated that the dual D2 and 5-HT1A receptor antagonist 9f could serve as a promising lead compound to discover potent antipsychotic agents.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  5-HT(2A) receptor antagonist; Antipsychotic; D(2) receptor antagonist; Molecular hybridization; Multi-target strategy

Year:  2020        PMID: 32182489     DOI: 10.1016/j.ejmech.2020.112214

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

Review 1.  Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors.

Authors:  Hongguang Ma; Boshi Huang; Yan Zhang
Journal:  Drug Discov Today       Date:  2020-07-09       Impact factor: 7.851

2.  Anticancer Effects with Molecular Docking Confirmation of Newly Synthesized Isatin Sulfonamide Molecular Hybrid Derivatives against Hepatic Cancer Cell Lines.

Authors:  Mahmoud Eldeeb; Eman F Sanad; Ahmed Ragab; Yousry A Ammar; Khaled Mahmoud; Mamdouh M Ali; Nadia M Hamdy
Journal:  Biomedicines       Date:  2022-03-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.